Therapy News and Research

RSS

Merck's NOXAFIL injection gets FDA approval for intravenous use

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved NOXAFIL (posaconazole) injection (18 mg/ mL), a new formulation of NOXAFIL for intravenous (IV) use.

16 Mar 2014

Scientists uncover how inflammation and lack of oxygen cause brain damage

Scientists have uncovered how inflammation and lack of oxygen conspire to cause brain damage in conditions such as stroke and Alzheimer's disease.

14 Mar 2014

Stem cell therapy may benefit patients with debilitating heart failure

Researchers want to know whether patients with debilitating heart failure can benefit by having their own stem cells injected into their ailing heart muscle.

14 Mar 2014

MD Anderson collaborates with MedImmune to develop therapies that unleash patients' immune systems to attack cancers

The University of Texas MD Anderson Cancer Center and MedImmune, the global biologics research and development arm of AstraZeneca, will collaborate through MD Anderson's Moon Shots Program to develop therapies that unleash patients' immune systems to attack their cancers.

14 Mar 2014

Researchers find effective strategy to eliminate cancer stem-like cells

Combining nanodrug-based chemotherapy and cryoablation provides an effective strategy to eliminate cancer stem-like cells (CSCs) the root of cancer resistance and metastasis, which will help to improve the safety and efficacy of treating malignancies that are refractory to conventional therapies.

14 Mar 2014

Positive margins have limited impact on RCC outcome

Positive vascular wall margins are not associated with systemic recurrence or cancer-specific survival in patients with nonmetastatic renal cell carcinoma with tumour thrombus, US research shows.

13 Mar 2014

Japanese PAH patient prognosis ‘good’

Japanese patients respond well to pulmonary arterial hypertension-targeted drugs and may have a good prognosis with long-term survival, study findings suggest.

13 Mar 2014

PhotoMedex Q4 2013 revenues up 16% to $63.5 million

PhotoMedex, Inc. today announced financial results for the fourth quarter and full year ended December 31, 2013.

13 Mar 2014

Transamerica obtains 4-star Medicare Part D rating from CMS for 2014

Transamerica continues to provide exceptional value to Medicare customers by obtaining a 4-star Medicare Part D rating from the Centers for Medicare and Medicaid Services for 2014.

13 Mar 2014

AnaptysBio announces strategic immuno-oncology collaboration with TESARO

AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies, today announced a strategic immuno-oncology collaboration with TESARO, Inc., an oncology-focused biopharmaceutical company.

13 Mar 2014

Discovery Laboratories reports net loss of $11.7 million for fourth quarter 2013

Discovery Laboratories, Inc., a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced financial results for the fourth quarter ended December 31, 2013, as well as recent business updates.

13 Mar 2014

Investigators urge drug regulators to provide clear evidence on statins’ side effects

At a time when the wider prescription of statins is under renewed public scrutiny, a substantial analysis of placebo-controlled randomised trials of statins has found that only a small minority of side effects reported by those taking the cholesterol-lowering drugs are actually attributable to them.

13 Mar 2014

Highlighting relationships in advertisements and promotions can radically impact sales

Valentine's Day has come and gone. But those images of romance are still everywhere : a happy couple holding hands in an eharmony ad, two lovebirds sharing a tender kiss in a Nikon camera commercial.

13 Mar 2014

Two synergistic therapies allow solid tumors to act as their own cancer-fighting vaccine

Researchers in the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute eradicated solid tumors in laboratory mice using a novel combination of two targeted agents. These two synergistic therapies stimulate an immune response, ultimately allowing solid tumors to act as their own cancer-fighting vaccine.

13 Mar 2014

Researchers identify new player in onset and progression of heart failure

A team of cardiovascular researchers from the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai, Sanford-Burnham Medical Research Institute, and University of California, San Diego have identified a small, but powerful, new player in the onset and progression of heart failure.

13 Mar 2014

iCAD prices underwritten public offering of 2,400,000 shares of common stock

iCAD, Inc. ("iCAD"), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy solutions for the early identification and treatment of cancer, today announced it has priced a registered firm commitment underwritten public offering of 2,400,000 shares of its common stock at a price to public of $11.00 per share.

12 Mar 2014

EPFL sets up foundation to release antibiotic for tuberculosis

Even though tuberculosis kills more than 1.5 million people every year, the market is not cost-effective for pharmaceutical companies. So EPFL is setting up a foundation to release an antibiotic developed in its own laboratories under EU funding.

12 Mar 2014

STC Life and 97.7 B&H Clinic successfully treat pulmonary fibrosis patient

Stem cell research institute of STC Life Co., Ltd. (Chairman: KYE HO LEE) and 97.7 B&H Clinic (Representative Doctor: WON JU JUNG) successfully finished mesenchymal stem cell therapy for the pulmonary fibrosis patient who visited Korea from Calgary, Canada.

12 Mar 2014

MUSC, Alliance Oncology announce strategic radiation therapy affiliation

The Medical University of South Carolina (MUSC), one of the nation's top academic health science centers, and Alliance Oncology, a division of Alliance HealthCare Services, Inc., announce a newly formed affiliation designed to strengthen and expand MUSC's Hollings Cancer Center as the radiation therapy market leader in Charleston, South Carolina.

12 Mar 2014

MEDIAN Technologies inks €700K deal with leading pharmaceutical company

MEDIAN Technologies, a leading medical imaging software solutions developer and a service provider for image interpretation and management in oncology clinical trials, today announced it has signed a contract with a global top five pharmaceutical company.

12 Mar 2014